.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Cerilliant
Covington
Baxter
Daiichi Sankyo
Federal Trade Commission
Merck
US Army
Colorcon

Generated: November 22, 2017

DrugPatentWatch Database Preview

NEURACEQ Drug Profile

« Back to Dashboard

What is the patent landscape for Neuraceq, and when can generic versions of Neuraceq launch?

Neuraceq is a drug marketed by Piramal Imaging and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-three patent family members in twenty-five countries and fifteen supplementary protection certificates in twelve countries.

The generic ingredient in NEURACEQ is florbetaben f-18. One supplier is listed for this compound. Additional details are available on the florbetaben f-18 profile page.

Summary for NEURACEQ

Pharmacology for NEURACEQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Piramal Imaging
NEURACEQ
florbetaben f-18
SOLUTION;INTRAVENOUS204677-001Mar 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Piramal Imaging
NEURACEQ
florbetaben f-18
SOLUTION;INTRAVENOUS204677-001Mar 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NEURACEQ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,072Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
8,465,726Stilbene derivatives and their use for binding and imaging amyloid plaques► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NEURACEQ

Country Document Number Estimated Expiration
Mexico2007007380► Subscribe
South Africa200705104► Subscribe
Norway339195► Subscribe
Netherlands300719► Subscribe
Slovenia2213652► Subscribe
European Patent Office2213652► Subscribe
Singapore194363► Subscribe
BrazilPI0516408► Subscribe
European Patent Office1838298► Subscribe
Canada2591534► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NEURACEQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1 2-2015Slovakia► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224
0719Netherlands► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140224
C0012France► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140224
2015 00018Denmark► SubscribePRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140224
2015 00018Denmark► SubscribePRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140220
0150010 00142Estonia► SubscribePRODUCT NAME: FLORBETABEEN (18F);REG NO/DATE: EU/1/13/906 24.02.2014
2015000018Germany► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
2015005Lithuania► SubscribePRODUCT NAME: FLORBETABENUM (18F); REGISTRATION NO/DATE: EU/1/13/906/001 20140220
00719Netherlands► SubscribePRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: EU/1/13/906 20140220
90005-3Sweden► SubscribePRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906 20140224
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Baxter
Colorcon
Cantor Fitzgerald
Fish and Richardson
Cipla
Teva
US Department of Justice
McKesson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot